Literature DB >> 19782116

Caffeine and CSC, adenosine A2A antagonists, offer neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells.

Hélio Vitoriano Nobre1, Geanne Matos de Andrade Cunha, Lissiana Magna de Vasconcelos, Hemerson Iury Ferreira Magalhães, Raimundo Nogueira Oliveira Neto, Flávio Damasceno Maia, Manoel Odorico de Moraes, L Kalyne A Moreira Leal, Glauce Socorro de Barros Viana.   

Abstract

In this study, the cytoprotective effects of caffeine (CAF) and 8-(3-chlorostyryl)-caffeine (CSC), A(2A) receptor antagonists, were tested against 6-OHDA-induced cytotoxicity, in rat mesencephalic cells. Both drugs significantly increased the number of viable cells, after their exposure to 6-OHDA, as measured by the MTT assay. While nitrite levels in the cells were drastically increased by 6-OHDA, their concentrations were brought toward normality after CAF or CSC, indicating that both drugs block 6-OHDA-induced oxidative stress which leads to free radicals generation. A complete blockade of 6-OHDA-induced lipid peroxidation, considered as a major source of DNA damage, was observed after cells treatment with CAF or CSC. 6-OHDA decreased the number of normal cells while increasing the number of apoptotic cells. In the CAF plus 6-OHDA group, a significant recover in the number of viable cells and a decrease in the number of apoptotic cells were seen, as compared to the group treated with 6-OHDA alone. A similar effect was observed after cells exposure to CSC in the presence of 6-OHDA. Unexpectedly, while a significant lower number of activated microglia was observed after cells exposure to CAF plus 6-OHDA, this was not the case after cells exposure to CSC under the same conditions. While CAF lowered the percentage of reactive astrocytes increased by 6-OHDA, CSC presented no effect. The effects of these drugs were also examined on the releases of myeloperoxidase (MPO), an inflammatory marker, and lactate dehydrogenase (LDH), a marker for cytotoxicity, in human neutrophils, in vitro. CSC and CAF (0.1, 1 and 10 microg/ml) produced inhibitions of the MPO release from PMA-stimulated cells, ranging from 45 to 83%. In addition, CSC and CAF (5, 50 and 100 microg/ml) did not show any cytotoxicity in the range of concentrations used, as determined by the LDH assay. All together, our results showed a strong neuroptrotection afforded by caffeine or CSC, on rat mesencephalic cells exposed to 6-OHDA. Furthermore, CSC and caffeine actions, inhibiting MPO as well as LDH releases, would contribute to their possible benefit in the treatment of neurodegenerative diseases, including DP. These effects are partially due to the ability of these A(2A) antagonists to decrease the cells free radicals production and oxidative stress, that are major components of 6-OHDA-induced cytotoxicity. 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782116     DOI: 10.1016/j.neuint.2009.09.001

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  16 in total

Review 1.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

2.  Differential Effect of Caffeine Consumption on Diverse Brain Areas of Pregnant Rats.

Authors:  Inmaculada Ballesteros-Yáñez; Carlos Alberto Castillo; Mariano Amo-Salas; José Luis Albasanz; Mairena Martín
Journal:  J Caffeine Res       Date:  2012-06

3.  Adenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum.

Authors:  James W Bogenpohl; Stefanie L Ritter; Randy A Hall; Yoland Smith
Journal:  J Comp Neurol       Date:  2012-02-15       Impact factor: 3.215

4.  Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease.

Authors:  Krystyna Gołembiowska; Jadwiga Wardas; Karolina Noworyta-Sokołowska; Katarzyna Kamińska; Anna Górska
Journal:  Neurotox Res       Date:  2013-01-08       Impact factor: 3.911

Review 5.  The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects.

Authors:  Beáta Sperlágh; E Sylvester Vizi
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

6.  Caffeine and sleep-deprivation mediated changes in open-field behaviours, stress response and antioxidant status in mice.

Authors:  J Olakunle Onaolapo; Y Adejoke Onaolapo; A Moses Akanmu; Gbola Olayiwola
Journal:  Sleep Sci       Date:  2016-11-12

7.  Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges.

Authors:  Rafael Franco; Gemma Navarro
Journal:  Front Psychiatry       Date:  2018-03-12       Impact factor: 4.157

Review 8.  Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental models of Parkinson's disease.

Authors:  Sushruta Koppula; Hemant Kumar; Sandeep Vasant More; Hyung-Woo Lim; Soon-Min Hong; Dong-Kug Choi
Journal:  Molecules       Date:  2012-09-26       Impact factor: 4.411

Review 9.  Microglial Adenosine Receptors: From Preconditioning to Modulating the M1/M2 Balance in Activated Cells.

Authors:  Rafael Franco; Alejandro Lillo; Rafael Rivas-Santisteban; Irene Reyes-Resina; Gemma Navarro
Journal:  Cells       Date:  2021-05-07       Impact factor: 6.600

10.  Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage.

Authors:  Raquel Boia; Filipe Elvas; Maria H Madeira; Inês D Aires; Ana C Rodrigues-Neves; Pedro Tralhão; Eszter C Szabó; Younis Baqi; Christa E Müller; Ângelo R Tomé; Rodrigo A Cunha; António F Ambrósio; Ana R Santiago
Journal:  Cell Death Dis       Date:  2017-10-05       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.